The pharmacokinetics of single doses of metoclopramide in renal failure

Eur J Clin Pharmacol. 1981;19(6):437-41. doi: 10.1007/BF00548588.


The pharmacokinetics of metoclopramide have been studied after intravenous and oral dosing (10 mg) to 6 patients with chronic renal failure. The mean terminal half-life was 13.9 h after intravenous and 14.8 h after oral administration. Total body clearance after i.v. dosing was 16.7 l/h. Oral bioavailability was 71.8%. In comparison to previous studies on normal subjects these results indicate that clearance of metoclopramide in renal failure is approximately 30% of normals. This difference is not accounted for by the change in renal clearance and suggests impaired metabolism or an alteration in enterohepatic circulation of metoclopramide in renal failure.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biological Availability
  • Female
  • Humans
  • Kidney Failure, Chronic / metabolism*
  • Kinetics
  • Male
  • Metabolic Clearance Rate
  • Metoclopramide / metabolism*
  • Middle Aged


  • Metoclopramide